MCID: PRG002
MIFTS: 36

Progesterone-Receptor Positive Breast Cancer malady

Categories: Cancer diseases

Aliases & Classifications for Progesterone-Receptor Positive Breast Cancer

Aliases & Descriptions for Progesterone-Receptor Positive Breast Cancer:

Name: Progesterone-Receptor Positive Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060077

Summaries for Progesterone-Receptor Positive Breast Cancer

MalaCards based summary : Progesterone-Receptor Positive Breast Cancer is related to breast cancer and bartholin's gland benign neoplasm. An important gene associated with Progesterone-Receptor Positive Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Glioma and Prolactin Signaling Pathway. The drugs Anastrozole and Exemestane have been mentioned in the context of this disorder. Affiliated tissues include breast and endothelial, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Progesterone-Receptor Positive Breast Cancer

Diseases in the Progesterone-Receptor Positive Breast Cancer family:

Progesterone-Receptor Negative Breast Cancer

Diseases related to Progesterone-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
id Related Disease Score Top Affiliating Genes
1 breast cancer 10.5
2 bartholin's gland benign neoplasm 10.2 ESR1 PGR
3 cardiovascular organ benign neoplasm 10.2 ESR1 PGR
4 appendix leiomyoma 10.2 ESR1 PGR
5 bronchus adenoma 10.2 ESR1 PGR
6 ovarian benign neoplasm 10.2 ESR1 PGR
7 plexiform neurofibroma 10.2 ESR1 PGR
8 paranasal sinus disease 10.2 ESR1 PGR
9 atypical lipomatous tumor 10.2 ESR1 PGR
10 pediatric intraocular retinoblastoma 10.2 ESR1 PGR
11 congenital disorder of glycosylation, type ic 10.2 ESR1 PGR
12 intestinal perforation 10.2 ESR1 PGR
13 perlman syndrome 10.2 ESR1 PGR
14 bladder adenocarcinoma 10.2 ESR1 PGR
15 anal neuroendocrine tumor 10.2 ESR1 PGR
16 biemond syndrome 10.2 CYP19A1 PGR
17 vulva basal cell carcinoma 10.2 ESR1 PGR
18 villoglandular endometrial endometrioid adenocarcinoma 10.1 ESR1 PGR
19 panophthalmitis 10.1 CYP19A1 PGR
20 vaginal adenosarcoma 10.1 ESR1 PGR
21 intraneural perineurioma 10.1 ESR1 PGR
22 middle ear adenocarcinoma 10.1 ESR1 PGR
23 paraphimosis 10.1 ESR1 PGR
24 mucoepidermoid esophageal carcinoma 10.1 ESR1 PGR
25 adult neuronal ceroid lipofuscinosis 10.1 ESR1 PGR
26 mouth disease 10.1 ERBB2 PGR
27 vulvar alveolar soft part sarcoma 10.1 ESR1 PGR
28 ovarian clear cell malignant adenofibroma 10.1 ESR1 PGR
29 mucoepidermoid thyroid carcinoma 10.1 ERBB2 PGR
30 triple-receptor negative breast cancer 10.1 ERBB2 PGR
31 pilar sheath acanthoma 10.1 ESR1 PGR
32 skin sarcoma 10.1 ERBB2 PGR
33 osteoblastoma 10.1 ESR1 PGR
34 celiac disease 12 10.1 CYP19A1 ESR1
35 intestinal neuroendocrine benign tumor 10.1 ERBB2 PGR
36 lung clear cell carcinoma 10.1 ESR1 PGR
37 adams-oliver syndrome 6 10.1 CYP19A1 ESR1
38 migraine with aura 10.1 ESR1 PGR
39 basaloid squamous cell carcinoma 10.1 ERBB2 PGR
40 infiltrating angiolipoma 10.1 ERBB2 PGR
41 biliary tract neoplasm 10.1 ESR1 PGR
42 larynx leiomyoma 10.1 CYP19A1 ESR1
43 hereditary breast ovarian cancer 10.1 ERBB2 ESR1
44 liver sarcoma 10.1 CYP19A1 ESR1
45 epithelioid neurofibroma 10.1 ESR1 PGR
46 gangliosidosis gm1 10.1 ESR1 PGR
47 sex differentiation disease 10.1 CYP19A1 PGR
48 gastrointestinal system cancer 10.1 ERBB2 PGR
49 van regemorter pierquin vamos syndrome 10.1 CYP19A1 ESR1
50 immunodeficiency due to a late component of complement deficiency 10.1 ERBB2 PGR

Graphical network of the top 20 diseases related to Progesterone-Receptor Positive Breast Cancer:



Diseases related to Progesterone-Receptor Positive Breast Cancer

Symptoms & Phenotypes for Progesterone-Receptor Positive Breast Cancer

MGI Mouse Phenotypes related to Progesterone-Receptor Positive Breast Cancer:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 ESR1 CYP19A1 ESR2 ERBB2 PGR
2 cardiovascular system MP:0005385 9.89 ESR1 CYP19A1 ESR2 ERBB2 PGR
3 cellular MP:0005384 9.88 PGR ESR1 CYP19A1 ESR2 ERBB2
4 endocrine/exocrine gland MP:0005379 9.83 CYP19A1 ESR2 ERBB2 PGR ESR1
5 integument MP:0010771 9.8 CYP19A1 ESR2 ERBB2 PGR ESR1
6 digestive/alimentary MP:0005381 9.76 ESR1 CYP19A1 ESR2 ERBB2
7 muscle MP:0005369 9.72 CYP19A1 ESR2 ERBB2 PGR ESR1
8 limbs/digits/tail MP:0005371 9.67 ESR1 ESR2 ERBB2 PGR
9 neoplasm MP:0002006 9.56 ESR1 ESR2 ERBB2 PGR
10 normal MP:0002873 9.55 CYP19A1 ESR2 ERBB2 PGR ESR1
11 reproductive system MP:0005389 9.35 CYP19A1 ESR2 ERBB2 PGR ESR1
12 skeleton MP:0005390 9.02 ESR1 CYP19A1 ESR2 ERBB2 PGR

Drugs & Therapeutics for Progesterone-Receptor Positive Breast Cancer

Drugs for Progesterone-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 3,Phase 2,Phase 1 120511-73-1 2187
2
Exemestane Approved, Investigational Phase 3,Phase 2,Phase 1 107868-30-4 60198
3
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1 112809-51-5 3902
4
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
5
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
6
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
10
Goserelin Approved Phase 3,Phase 2 65807-02-5 47725 5311128
11
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
12
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
13
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
14
Fulvestrant Approved, Investigational Phase 3,Phase 2,Phase 1 129453-61-8 104741 17756771
15
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
16
Zoledronic acid Approved Phase 3,Phase 2 118072-93-8 68740
17
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
18
Lenograstim Approved Phase 3,Phase 2 135968-09-1
19
Triamcinolone Approved, Vet_approved Phase 3,Phase 2 124-94-7 31307
20
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
21
Toremifene Approved, Investigational Phase 2, Phase 3 89778-26-7 3005573
22
Everolimus Approved Phase 3,Phase 2 159351-69-6 6442177
23
Leuprolide Approved, Investigational Phase 3,Phase 2 53714-56-0 3911 657181
24
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
25
Sirolimus Approved, Investigational Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
26
Methyltestosterone Approved Phase 3 58-18-4 6010
27
Testosterone Approved, Investigational Phase 3 58-22-0 6013
28
Pembrolizumab Approved Phase 3,Phase 2 1374853-91-4
29
Pertuzumab Approved Phase 3,Phase 2 145040-37-5, 380610-27-5 2540
30
Denosumab Approved Phase 3,Phase 2 615258-40-7
31
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
32
Metformin Approved Phase 3 657-24-9 14219 4091
33
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
34
Norepinephrine Approved Phase 3 51-41-2 439260
35
Succinylcholine Approved Phase 3 306-40-1 5314
36
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
37
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
38
Fenretinide Investigational Phase 3 65646-68-6
39
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2,Phase 1 231277-92-2, 388082-78-8 208908 9941095
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
41 Aromatase Inhibitors Phase 3,Phase 2,Phase 1
42 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1
43 Estrogen Antagonists Phase 3,Phase 2,Phase 1
44 Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
45 Estrogens Phase 3,Phase 2,Phase 1
46 Hormone Antagonists Phase 3,Phase 2,Phase 1
47 Hormones Phase 3,Phase 2,Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
49 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
50 Steroid Synthesis Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 163)
id Name Status NCT ID Phase
1 Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery Unknown status NCT00541086 Phase 3
2 Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00893061 Phase 3
3 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3
4 Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women Unknown status NCT00912548 Phase 3
5 Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy Completed NCT00050011 Phase 3
6 Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer Completed NCT00002646 Phase 3
7 S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Completed NCT01385137 Phase 3
8 Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer Completed NCT00330317 Phase 3
9 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3
10 Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients Recruiting NCT02132000 Phase 2, Phase 3
11 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Recruiting NCT01674140 Phase 3
12 Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment Recruiting NCT01573442 Phase 3
13 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Recruiting NCT02115282 Phase 3
14 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Recruiting NCT01272037 Phase 3
15 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3
16 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02488967 Phase 3
17 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer Recruiting NCT01805076 Phase 3
18 Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer Active, not recruiting NCT00073528 Phase 3
19 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066703 Phase 3
20 Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02 Active, not recruiting NCT00975676 Phase 3
21 S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Active, not recruiting NCT02137837 Phase 3
22 A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Active, not recruiting NCT01101438 Phase 3
23 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3
24 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3
25 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases Active, not recruiting NCT00072293 Phase 3
26 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Active, not recruiting NCT01598298 Phase 3
27 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Active, not recruiting NCT00433589 Phase 3
28 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
29 Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02 Active, not recruiting NCT00963417 Phase 3
30 Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer Active, not recruiting NCT00601900 Phase 3
31 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Active, not recruiting NCT02003209 Phase 3
32 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066690 Phase 3
33 Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Active, not recruiting NCT00390455 Phase 3
34 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Active, not recruiting NCT01275677 Phase 3
35 Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Active, not recruiting NCT00310180 Phase 3
36 Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Active, not recruiting NCT00785291 Phase 3
37 Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer Active, not recruiting NCT00463489 Phase 3
38 Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy Active, not recruiting NCT00556374 Phase 3
39 Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients Active, not recruiting NCT00130533 Phase 3
40 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting NCT00063999 Phase 3
41 Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer Not yet recruiting NCT03078751 Phase 3
42 Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer Not yet recruiting NCT03081234 Phase 3
43 A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer Terminated NCT01548534 Phase 3
44 STRIDE - STimulating Immune Response In aDvanced brEast Cancer Terminated NCT00925548 Phase 3
45 Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer Withdrawn NCT00053339 Phase 3
46 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Unknown status NCT01124695 Phase 2
47 Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer Unknown status NCT00687648 Phase 2
48 Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer Unknown status NCT00871858 Phase 2
49 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Unknown status NCT00856492 Phase 2
50 Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers Unknown status NCT02052128 Phase 1, Phase 2

Search NIH Clinical Center for Progesterone-Receptor Positive Breast Cancer

Genetic Tests for Progesterone-Receptor Positive Breast Cancer

Anatomical Context for Progesterone-Receptor Positive Breast Cancer

MalaCards organs/tissues related to Progesterone-Receptor Positive Breast Cancer:

39
Breast, Endothelial

Publications for Progesterone-Receptor Positive Breast Cancer

Articles related to Progesterone-Receptor Positive Breast Cancer:

(show all 16)
id Title Authors Year
1
Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. ( 26161666 )
2015
2
Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer. ( 26363528 )
2015
3
Clinical significance of SPRR1A expression in progesterone receptor-positive breast cancer. ( 25424702 )
2015
4
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. ( 23971947 )
2013
5
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. ( 23579222 )
2013
6
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. ( 23788750 )
2013
7
Progesterone and levonorgestrel regulate expression of 17I^HSD-enzymes in progesterone receptor positive breast cancer cell line T47D. ( 22564730 )
2012
8
A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. ( 22548922 )
2012
9
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. ( 20705559 )
2010
10
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. ( 19130322 )
2009
11
Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? ( 19703124 )
2009
12
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. ( 18302747 )
2008
13
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. ( 16467123 )
2006
14
Estrogen receptor alpha-negative and progesterone receptor-positive breast cancer: lab error or real entity? ( 17189985 )
2006
15
Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer. ( 12408471 )
2002
16
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. ( 9196144 )
1997

Variations for Progesterone-Receptor Positive Breast Cancer

Expression for Progesterone-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Progesterone-Receptor Positive Breast Cancer.

Pathways for Progesterone-Receptor Positive Breast Cancer

Pathways related to Progesterone-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 12)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.48 ERBB2 ESR1 ESR2 PGR
2
Show member pathways
12.1 ERBB2 ESR1 ESR2
3
Show member pathways
11.87 ERBB2 ESR1 ESR2
4 11.51 ESR1 ESR2
5
Show member pathways
11.47 ERBB2 ESR1 PGR
6
Show member pathways
11.46 ERBB2 ESR1
7
Show member pathways
11.29 ESR1 ESR2 PGR
8 10.9 ESR1 ESR2
9 10.85 ESR1 ESR2
10 10.77 ESR1 ESR2
11 10.64 CYP19A1 ESR2 PGR
12 9.4 CYP19A1 ESR1 ESR2

GO Terms for Progesterone-Receptor Positive Breast Cancer

Biological processes related to Progesterone-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.37 ESR1 ESR2
2 intracellular estrogen receptor signaling pathway GO:0030520 9.32 ESR1 ESR2
3 androgen metabolic process GO:0008209 9.26 CYP19A1 ESR1
4 uterus development GO:0060065 9.16 CYP19A1 ESR1
5 transcription initiation from RNA polymerase II promoter GO:0006367 9.13 ESR1 ESR2 PGR
6 steroid hormone mediated signaling pathway GO:0043401 8.8 ESR1 ESR2 PGR

Molecular functions related to Progesterone-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.67 ESR1 ESR2 PGR
2 enzyme binding GO:0019899 9.61 ESR1 ESR2 PGR
3 lipid binding GO:0008289 9.58 ESR1 ESR2 PGR
4 ATPase binding GO:0051117 9.48 ESR1 PGR
5 core promoter sequence-specific DNA binding GO:0001046 9.46 ESR1 ESR2
6 steroid hormone receptor activity GO:0003707 9.43 ESR1 ESR2 PGR
7 estrogen receptor activity GO:0030284 9.37 ESR1 ESR2
8 estrogen response element binding GO:0034056 9.32 ESR1 ESR2
9 RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding GO:0038052 9.16 ESR1 ESR2
10 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.13 ESR1 ESR2 PGR
11 steroid binding GO:0005496 8.8 ESR1 ESR2 PGR

Sources for Progesterone-Receptor Positive Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....